HpHMG联合炔雌醇环丙孕酮治疗多囊卵巢综合征不孕的效果

摘要/Abstract

摘要： 目的：探究高浓度尿促性素（HpHMG）联合炔雌醇环丙孕酮治疗对多囊卵巢综合征（PCOS）不孕患者卵巢功能及黄体生成素（LH）、睾酮（T）、黄体生成素/卵泡刺激素（LH/FSH）水平的影响。方法：选取我院妇产科2019年6月至2020年6月接受诊治的84例PCOS不孕症患者作为研究对象，按照随机数字表法将所有患者分为观察组（n=42）和对照组（n=42）。对照组患者给予炔雌醇环丙孕酮片口服治疗，观察组患者在此基础上予以HpHMG注射治疗。两组患者均以21 d为1个治疗周期，连续治疗3个周期。比较两组患者治疗后临床疗效，治疗前后性激素水平、卵巢功能，统计治疗期间不良反应，治疗后24个月随访观察两组患者排卵及妊娠情况。结果：观察组患者治疗总有效率为92.86%，高于对照组的76.19%（P<0.05）。治疗后，两组患者卵巢的体积均较治疗前减小，且观察组患者治疗后卵巢体积减小程度较对照组更为明显（P<0.05）；两组患者直径10~14 mm卵泡数、直径≥15 mm卵泡数及最大卵泡直径均较治疗前增加，观察组患者增加程度较对照组更为明显（P<0.05）。治疗后，两组患者LH、T、LH/FSH水平均较治疗前降低，观察组患者LH、T、LH/FSH水平降低程度较对照组更为明显（P<0.05）。两组患者不良反应发生率差异无统计学意义（7.14% vs. 11.90%，P=0.710）。随访期间，观察组患者排卵率及自然妊娠率分别为90.48%、59.52%，均高于对照组的71.43%、30.95%（P<0.05）。结论：HpHMG联合炔雌醇环丙孕酮可通过改善PCOS不孕症患者性激素水平，从而促进卵巢正常排卵，改善卵巢功能，提高患者自然受孕率，对PCOS不孕症治疗效果显著，且具有一定安全性。

关键词: font-size:medium, ">多囊卵巢综合征；不孕症；炔雌醇环丙孕酮；高浓度尿促性素；卵巢功能

Abstract: Objective：To investigate the effects of highlypurified menotropin (HpHMG) combined with ethinylestradiol and cyproterone on ovarian function and the levels of luteinizing hormone (LH)， testosterone (T)， luteinizing hormone/follicle stimulating hormone (LH/FSH) in patients with polycystic ovarian syndrome (PCOS) infertility.Methods： 84 patients with PCOS infertility who were diagnosed and treated in obstetrics and gynecology department of our hospital between June 2019 and June 2020 were randomly divided into the observation group (42 cases) and the control group (42 cases) according to the random number table method. The control group was treated with ethinylestradiol and cyproterone acetate tablets orally， and the observation group was treated with HpHMG injection on this basis. Both groups were treated for 3 consecutive cycles treatment with 21 d as one treatment cycle. The clinical efficacy after treatment， the level of sex hormone and ovarian status before and after treatment and 24 months followup after treatment were compared between the two groups. Adverse reactions during treatment were counted. Results：The total effective rate of the observation group was higher than that of the control group (92.86% vs 76.19%， P<0.05). After treatment， the volume of ovarie of patients in both groups was reduced， and the observation group was more obvious on the reduction degree of the volum of ovarie than the control group (P<0.05). The number of follicles with diameter of 10-14 mm， the number of follicles with diameter ≥15 mm and the maximum diameter of follicles in both groups were increased compared with those before treatment， and those in the observation group were higher than the control group(P<0.05). After treatment， the levels of LH， T， LH/FSH in the two groups were lower than those before treatment， and the degree of rduction in the observation group were more obvious than the control group (P<0.05). During the followup， the ovulation rate and natural pregnancy rate in the observation group were 90.48% and 59.52%， which were higher than 71.43% and 30.95% in the control group (P<0.05).There was no statistical difference in the incidence in adverse reactions between the two groups (7.14% vs. 11.90%， P=0.710). Conclusion： HpHMG combined with ethinylestradiol and cyclopropane can improve the level of sex hormones in patients with PCOS infertility， promote normal ovulation， improve the natural pregnancy rate of patients， which has significant effect in treating PCOS infertility， and it is safe.

Key words: font-size:medium, ">Polycystic ovarian syndrome； Infertility； Ethinylestradiol and cyproterone； Highlypurified menotropin； Ovarian function

中图分类号:

薛彩琴, 贺译平, 刘振国. HpHMG联合炔雌醇环丙孕酮治疗多囊卵巢综合征不孕的效果[J]. 中国医药导刊, 2022, 24(10): 993-997.

XUE Caiqin, HE Yiping, LIU Zhenguo. Effect of HpHMG Combined with Ethinylestradiol and Cyproterone in the Treatment of Infertility with Polycystic Ovarian Syndrome[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(10): 993-997.

参考文献

[1]佛新艳，唐红伟，李娜.炔雌醇环丙孕酮联合营养干预对PCOS患者的疗效及对患者AMH水平和排卵率的影响[J].临床和实验医学杂志，2019，18(24)： 26592662.
     [2]Ahmad AK， Kao CN， Quinn M， et al.Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects： results of a longitudinal study[J].Fertil Steril，2018，109(3)：526531.
     [3]马越，杜菲菲.炔雌醇环丙孕酮联合不同药物治疗PCOS对患者免疫因子和氧化应激因子的影响[J].河北医药，2019，41(21)： 32243227，3232.
     [4]闫娅妮.来曲唑联合小剂量尿促性素在不明原因不孕患者行夫精宫腔内人工授精中的临床疗效[J].中国优生与遗传杂志，2019，27(2)： 247250.
     [5]Rotterdam ESHRE/ASRMSponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome[J]. Fertil Steril， 2004， 81(1)：1925.
     [6]郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国中医药科技出版社，2002： 91.
     [7]徐铮铮，汪向红，李利玲，等.醋酸曲普瑞林注射液联合炔雌醇环丙孕酮片治疗PCOS不孕症的效果及对相关激素水平的影响[J].中国性科学，2020，29(4)：6366.
     [8]OttoBuczkowska E， Grzyb K， Jainta N.Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty[J].Pediatr Endocrinol Diabetes Metab， 2018， 24(1)：4044.
     [9]李明群.炔雌醇环丙孕酮片联合奥利司他治疗肥胖型多囊卵巢综合征不孕患者的效果观察[J].中国妇幼保健，2019，34(21)： 50055008.
     [10]任玮玮，孙林.促性腺激素释放激素激动剂，绒毛膜促性腺激素在枸橼酸氯米芬联合人绝经期促性腺激素促排卵治疗多囊卵巢综合征不孕中的应用效果比较[J].中国医师进修杂志，2020，43(6)：560563.
     [11]郑晨，肖新春，朱虹丽，等.从"肾藏精"论多囊卵巢综合征与外泌体的关系[J].现代中西医结合杂志，2020，29(8)：909912.
     [12]党晓丽.炔雌醇环丙孕酮和二甲双胍联合治疗多囊卵巢综合征合并不孕症的效果及对激素水平的影响评价[J].贵州医药，2019，43(6)： 915916.
     [13]赵海君，张皙卉，卢静，等.高纯度人绝经期促性腺激素对不同年龄卵巢储备功能正常不孕患者体外受精胚胎移植结局的影响[J].新乡医学院学报，2022，39(6)：544547.
     [14]刘冬.来曲唑联合HpHMG对多囊卵巢综合征所致不孕症患者治疗效果研究[J].中国妇幼保健，2019，34(16)： 37663768.
     [15]陈乐，杨硕，尤昭玲，等.补肾调泡周期法对多囊卵巢模型大鼠卵巢AMH及AMHR Ⅱ表达的调控[J].中药新药与临床药理，2019，30(11)： 13141321.
     [16]刘霞，王琳.多囊卵巢综合征所致不孕者不同卵泡期HMG促排卵方案的效果随访分析[J].中南医学科学杂志，2020，48(1)：3234.
     [17]赵海君，陈静，卢静，等.含HCG 活性的高纯度尿促性素对高龄不孕患者体外受精的影响[J].皖南医学院学报，2022，41(3)：221224.
     [18]李可君，陈绍正.来曲唑联合炔雌醇环丙孕酮对多囊卵巢综合征患者促排卵效果的影响[J].中国妇幼保健，2021，36(4)：856860.
     [19]纪冬梅，邹薇薇，邓晓红，等.尿促性素促排卵在卵巢功能正常的不孕患者首次行IVFET助孕中的价值[J].安徽医学，2020，41(5)：501504.
     [20]白淑芳，柏璐，白雅维，等.来曲唑分别联合氯米芬与尿促性腺激素治疗对多囊卵巢综合征患者血清性激素及COR水平的影响[J].解放军医药杂志，2019，31(8)： 9599.
     [21]Deeks ED. Highly purified human menopausal gonadotropin (Menopur)： a profile of its use in infertility[J].Clin Drug Investig，2018，38(11)：10771084.

快速检索引用检索图表检索高级检索